Barclays Boosts Avantor (NYSE:AVTR) Price Target to $26.00

Avantor (NYSE:AVTR) had its price target raised by equities researchers at Barclays from $25.00 to $26.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective indicates a potential upside of 17.20% from the company’s current price.

Other research analysts also recently issued research reports about the company. Raymond James lowered their target price on Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company dropped their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group reiterated a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Avantor currently has a consensus rating of “Moderate Buy” and an average target price of $27.46.

Avantor Price Performance

Shares of AVTR stock traded down $0.10 during trading hours on Monday, reaching $22.19. The company’s stock had a trading volume of 2,279,693 shares, compared to its average volume of 4,626,846. Avantor has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The firm’s 50 day simple moving average is $21.69 and its 200-day simple moving average is $23.46. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $15.10 billion, a price-to-earnings ratio of 48.11, a PEG ratio of 3.97 and a beta of 1.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AVTR. MassMutual Private Wealth & Trust FSB raised its stake in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after buying an additional 625 shares during the last quarter. UMB Bank n.a. bought a new position in shares of Avantor in the 3rd quarter worth about $49,000. Global Retirement Partners LLC lifted its stake in shares of Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after purchasing an additional 1,067 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.